BR112014030404A2 - proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento - Google Patents

proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento

Info

Publication number
BR112014030404A2
BR112014030404A2 BR112014030404A BR112014030404A BR112014030404A2 BR 112014030404 A2 BR112014030404 A2 BR 112014030404A2 BR 112014030404 A BR112014030404 A BR 112014030404A BR 112014030404 A BR112014030404 A BR 112014030404A BR 112014030404 A2 BR112014030404 A2 BR 112014030404A2
Authority
BR
Brazil
Prior art keywords
hgh
fusion protein
growth hormone
treatment
hormone deficiency
Prior art date
Application number
BR112014030404A
Other languages
English (en)
Inventor
Spink Benjamin
Wang Chia-Wei
Humphriss Eric
M Bright George
L Cleland Jeffrey
Silverman Joshua
Geething Nathan
Schellenberger Volker
P Stemmer Willem
Original Assignee
Amunix Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Operating Inc filed Critical Amunix Operating Inc
Publication of BR112014030404A2 publication Critical patent/BR112014030404A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Abstract

resumo proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento a presente invenção diz respeito a um regime terapêutico melhorado para terapia ghd. em particular, a invenção diz respeito a métodos para a administração de uma dose em bolus de hormônio do crescimento humano xten (hgh-xten) proteína de fusão.
BR112014030404A 2012-06-05 2013-03-14 proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento BR112014030404A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261689390P 2012-06-05 2012-06-05
US201261663475P 2012-06-22 2012-06-22
US201361763753P 2013-02-12 2013-02-12
PCT/US2013/031673 WO2013184216A1 (en) 2012-06-05 2013-03-14 Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency

Publications (1)

Publication Number Publication Date
BR112014030404A2 true BR112014030404A2 (pt) 2017-06-27

Family

ID=47998551

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014030404A BR112014030404A2 (pt) 2012-06-05 2013-03-14 proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento

Country Status (17)

Country Link
US (2) US20140162949A1 (pt)
EP (1) EP2858664B1 (pt)
JP (2) JP2015520188A (pt)
KR (1) KR20150021072A (pt)
CN (2) CN107320719A (pt)
AU (1) AU2013272220A1 (pt)
BR (1) BR112014030404A2 (pt)
CA (1) CA2875827A1 (pt)
DK (1) DK2858664T3 (pt)
ES (1) ES2733220T3 (pt)
HK (1) HK1208629A1 (pt)
IL (1) IL236070A0 (pt)
MX (1) MX2014014927A (pt)
NZ (1) NZ702557A (pt)
PH (1) PH12014502738A1 (pt)
SG (1) SG11201408152VA (pt)
WO (1) WO2013184216A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
AU2014249258A1 (en) * 2013-03-11 2015-08-27 Amunix Operating Inc. Treatment of pediatric growth hormone deficiency with human growth hormone analogues
EA038329B1 (ru) 2015-08-28 2021-08-10 Амьюникс Фармасьютикалз, Инк. Химерный полипептидный комплекс и способы его получения и применения
WO2017136583A1 (en) 2016-02-02 2017-08-10 Versartis, Inc. Growth hormone treatment adherence system
EP3416677B1 (en) * 2016-02-17 2022-08-03 Genexine, Inc. Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
WO2017142331A1 (en) * 2016-02-17 2017-08-24 Genexine, Inc. Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
WO2018022939A1 (en) * 2016-07-27 2018-02-01 Amunix Operating Inc. Treatment of adult growth hormone deficiency with human growth hormone analogues
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN115322794A (zh) 2020-01-11 2022-11-11 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CA3193453A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
CN116554343A (zh) * 2022-01-30 2023-08-08 领诺(上海)医药科技有限公司 一种长效重组人生长激素及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898830A (en) 1979-07-05 1990-02-06 Genentech, Inc. Human growth hormone DNA
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6406632B1 (en) 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7294513B2 (en) 2002-07-24 2007-11-13 Wyatt Technology Corporation Method and apparatus for characterizing solutions of small particles
CN116925238A (zh) * 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
MX354555B (es) * 2009-06-08 2018-03-09 Amunix Operating Inc Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.

Also Published As

Publication number Publication date
AU2013272220A1 (en) 2015-01-15
US20180051063A1 (en) 2018-02-22
DK2858664T3 (da) 2019-07-08
EP2858664B1 (en) 2019-05-08
CN107320719A (zh) 2017-11-07
CA2875827A1 (en) 2013-12-12
CN104519903A (zh) 2015-04-15
JP2015520188A (ja) 2015-07-16
MX2014014927A (es) 2015-05-15
JP2017125051A (ja) 2017-07-20
US20140162949A1 (en) 2014-06-12
IL236070A0 (en) 2015-01-29
ES2733220T3 (es) 2019-11-28
WO2013184216A1 (en) 2013-12-12
PH12014502738A1 (en) 2015-02-02
HK1208629A1 (en) 2016-03-11
KR20150021072A (ko) 2015-02-27
NZ702557A (en) 2017-06-30
EP2858664A1 (en) 2015-04-15
SG11201408152VA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX2016002152A (es) Metodo para aumentar la expresion de proteinas codificadas por arn.
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
MY188139A (en) Sodium channel modulators for the treatment of pain
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
MX2016008013A (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp.
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
BR112014031088A8 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MY173215A (en) Acetylcysteine compositions and methods of use thereof
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
BR112018002530A2 (pt) combinações e usos e tratamentos destas
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
CY1125361T1 (el) Φαρμακευτικο παρασκευασμα υδατανθρακων για θεραπευτικη χρηση
MX2017002825A (es) Tratamientos medicos a base de anamorelina.
BR112015011099A2 (pt) Composições e métodos para o tratamento de diplasia ectodérmica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.